Assenagon Asset Management
ALNY icon

Assenagon Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Assenagon Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.9M Buy
155,695
+26,799
+21% +$8.08M 0.06% 238
2026
Q1 		$42.6M Buy
128,896
+103,306
+404% +$35.2M 0.06% 222
2025
Q4 		$10.2M Sell
25,590
-54,791
-68% -$24.2M 0.01% 507
2025
Q3 		$36.7M Buy
80,381
+62,695
+354% +$25.5M 0.05% 268
2025
Q2 		$5.77M Buy
17,686
+11,281
+176% +$3.12M 0.01% 550
2025
Q1 		$1.73M Sell
6,405
-13,513
-68% -$3.47M ﹤0.01% 795
2024
Q4 		$4.69M Buy
19,918
+2,285
+13% +$601K 0.01% 704
2024
Q3 		$4.85M Sell
17,633
-105,163
-86% -$27.4M 0.01% 727
2024
Q2 		$29.8M Buy
122,796
+62,454
+104% +$9.86M 0.07% 217
2024
Q1 		$9.02M Buy
60,342
+46,176
+326% +$7.7M 0.02% 458
2023
Q4 		$2.71M Buy
14,166
+7,436
+110% +$1.27M 0.01% 823
2023
Q3 		$1.19M Sell
6,730
-84,132
-93% -$16.1M ﹤0.01% 1004
2023
Q2 		$17.3M Sell
90,862
-124,329
-58% -$24.6M 0.06% 254
2023
Q1 		$43.1M Buy
215,191
+207,364
+2,649% +$43.6M 0.15% 124
2022
Q4 		$1.86M Buy
7,827
+1,569
+25% +$335K 0.01% 836
2022
Q3 		$1.25M Buy
+6,258
New +$1.19M ﹤0.01% 872
2022
Q1 		– Sell
-174,443
Closed -$29.6M – 1408
2021
Q4 		$29.6M Sell
174,443
-159,846
-48% -$29.7M 0.09% 165
2021
Q3 		$63.1M Buy
334,289
+50,489
+18% +$9.47M 0.2% 94
2021
Q2 		$48.1M Buy
283,800
+160,032
+129% +$23.4M 0.16% 111
2021
Q1 		$17.5M Buy
123,768
+101,135
+447% +$15.2M 0.07% 230
2020
Q4 		$2.94M Sell
22,633
-20,552
-48% -$2.74M 0.01% 445
2020
Q3 		$6.29M Sell
43,185
-75,334
-64% -$10.7M 0.04% 278
2020
Q2 		$17.6M Buy
118,519
+94,607
+396% +$12.8M 0.11% 119
2020
Q1 		$2.6M Buy
+23,912
New +$2.76M 0.02% 307
2019
Q4 		– Sell
-27,286
Closed -$2.19M – 751
2019
Q3 		$2.19M Buy
+27,286
New +$2.16M 0.01% 389

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Assenagon Asset Management's ALNY Position: Q2 2026 in Review

Assenagon Asset Management increased its Alnylam Pharmaceuticals (ALNY) stake by 21% in Q2 2026, buying an estimated $8.08M and bringing the position to 155,695 shares worth $46.9M. The position accounts for 0.06% of the portfolio, ranked #238.

Assenagon Asset Management first reported a position in ALNY in Q3 2019 and has held it in 25 quarters since. The position peaked at $63.1M in Q3 2021. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Assenagon Asset Management held 155,695 shares of Alnylam Pharmaceuticals worth $46.9M as of Q2 2026.
  • Assenagon Asset Management bought 26,799 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $8.08M.
  • Alnylam Pharmaceuticals made up 0.06% of Assenagon Asset Management's portfolio in Q2 2026, its #238 holding.
  • Assenagon Asset Management first reported a position in Alnylam Pharmaceuticals in Q3 2019 and has held it in 25 quarters since.
  • Assenagon Asset Management's Alnylam Pharmaceuticals position peaked at $63.1M in Q3 2021.
  • 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.